NASDAQ:AKRO

Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm

Retrieved on: 
Friday, May 31, 2024

NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for potential violations of the federal securities laws.

Key Points: 
  • NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for potential violations of the federal securities laws.
  • If you suffered a loss in Akero securities, and wish to participate, learn more, or discuss the issues surrounding the investigation, please contact attorneys at (914) 733-7256 or via email to Andrea Farah ( [email protected] ) or Vincent R. Cappucci Jr. ( [email protected] ).

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics

Retrieved on: 
Thursday, May 30, 2024
Patient, News, Liver disease, Food and Drug Administration, Advertising, Fatty liver disease, NASH, Cirrhosis, LLP, Court, EFX, Fibrosis, Cryptocurrency

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Akero’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • To learn more about the Akero Therapeutics class action, go to www.faruqilaw.com/AKRO or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.

DEADLINE ALERT for CMP, EXAI, AKRO, and MBUU: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Thursday, May 30, 2024
Patient, Compass Minerals, Risk, Åkerö, Investment, Suite, FDA, Defendant, Malibu Boats, NAFLD, NASH, Cirrhosis, Ethics, Law, EFX, Compass, Boat, Inflammation, Knowledge, Steatosis, Security (finance)

LOS ANGELES, May 30, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, May 30, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • The Law Offices of Frank R. Cruz, Los Angeles

Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against Akero Therapeutics, Inc. (AKRO)

Retrieved on: 
Saturday, June 1, 2024
Class Action Lawsuit, Professional Services, Legal, Patient, Non-alcoholic fatty liver disease, News, HERE, FDA, Therapy, Sale, Drug development, Fatty liver disease, Histology, 8-K, NASH, Cirrhosis, LLP, EFX, Fibrosis, District court, Lead, Pharmaceutical industry

The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of Akero’s materially misleading statements and omissions to the public, Akero’s investors have suffered significant losses.
  • If you suffered Akero losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/akero-therapeutics-inc?utm_source=PR&utm_...
    You can also contact attorney Jonathan Naji, Esq.
  • Kessler Topaz Meltzer & Check, LLP encourages Akero investors who have suffered significant losses to contact the firm directly to acquire more information.

AKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO

Retrieved on: 
Thursday, May 30, 2024
Lawyer, District court, Therapy, FREE, Åkerö

NEW ORLEANS, May 29, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 25, 2024 to file lead plaintiff applications in a securities class action lawsuit against Akero Therapeutics, Inc. (NasdaqGS: AKRO), if they purchased or otherwise acquired the Company’s shares between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”).

Key Points: 
  • NEW ORLEANS, May 29, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 25, 2024 to file lead plaintiff applications in a securities class action lawsuit against Akero Therapeutics, Inc. (NasdaqGS: AKRO), if they purchased or otherwise acquired the Company’s shares between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”).
  • This action is pending in the United States District Court for the Northern District of California.
  • Akero Therapeutics investors should visit us at https://claimsfiler.com/cases/nasdaq-akro/ or call toll-free (844) 367-9658.
  • Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

AKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO

Retrieved on: 
Wednesday, May 29, 2024
District court, KSF, Court

NEW ORLEANS, May 28, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 25, 2024 to file lead plaintiff applications in a securities class action lawsuit against Akero Therapeutics, Inc. (NasdaqGS: AKRO), if they purchased or otherwise acquired the Company’s shares between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”).

Key Points: 
  • NEW ORLEANS, May 28, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 25, 2024 to file lead plaintiff applications in a securities class action lawsuit against Akero Therapeutics, Inc. (NasdaqGS: AKRO), if they purchased or otherwise acquired the Company’s shares between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”).
  • This action is pending in the United States District Court for the Northern District of California.
  • If you purchased shares of Akero and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-akro/ to learn more.
  • If you wish to serve as a lead plaintiff in this class action, you must petition the Court by June 25, 2024.

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm

Retrieved on: 
Wednesday, May 29, 2024
Patient, Åkerö, Suite, FDA, Ethics, Certification, NASH, Cirrhosis, Complaint, Security (finance)

Investors who purchased the Company’s securities between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”), are encouraged to contact the firm before June 25, 2024.

Key Points: 
  • Investors who purchased the Company’s securities between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”), are encouraged to contact the firm before June 25, 2024.
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

DEADLINE ALERT for ADSK, CMP, AKRO, EXAI: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Wednesday, May 29, 2024
Patient, Compass Minerals, Class, Risk, Åkerö, Investment, Suite, FDA, Telephone, Defendant, NAFLD, NASH, Cirrhosis, Ethics, Law, EFX, Inflammation, Knowledge, Steatosis

BENSALEM, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at (215) 638-4847 or by email to [email protected] .
  • Law Offices of Howard G. Smith

AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Wednesday, May 29, 2024
Patient, News, Liver disease, FDA, DSM-IV codes, Sale, Drug development, Person, Fatty liver disease, Research, NASH, Cirrhosis, Court, EFX, Inflammation, Steatosis, Disclosure, Complaint

The Company has yet to generate any revenues because the FDA has not approved any of its drug candidates for sale.

Key Points: 
  • The Company has yet to generate any revenues because the FDA has not approved any of its drug candidates for sale.
  • To finance the Company’s operations, Akero conducted two secondary stock offerings and one at-the-market stock offering during the Class Period, raising over $577 million.
  • If you suffered a loss in Akero you have until June 25, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Akero Therapeutics (AKRO) SYMMETRY Study Under Fire in Class Action – AKRO Investors with Substantial Losses Encouraged to Contact Hagens Berman by June 25, 2024

Retrieved on: 
Tuesday, May 28, 2024
Patient, Clinical trial, FDA, Therapy, NASH, Cirrhosis, SAN, Hagens Berman, News, Liver disease, Fatty liver disease, Pharmaceutical industry

SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Akero Therapeutics, Inc. (NASDAQ: AKRO) investors who suffered substantial losses to submit their losses now .

Key Points: 
  • SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Akero Therapeutics, Inc. (NASDAQ: AKRO) investors who suffered substantial losses to submit their losses now .
  • Akero Therapeutics, a biopharmaceutical company developing treatments for liver disease, is under fire from investors in a securities class action lawsuit.
  • The lawsuit alleges that Akero misled investors about a key clinical trial designed to evaluate their lead drug candidate efruxifermin.
  • “We’re investigating whether Akero may have intentionally misrepresented the SYMMETRY trial’s design and results,” stated Reed Kathrein, the Hagens Berman partner leading the investigation.